- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
June 17th, 2007
Tempo Hurries To Target Nanoparticle Combo Drugs
Tempo Pharmaceuticals Inc. isn't wasting any time. Since its founding in late 2006, the Cambridge, Mass.-based company has raised Seed and Series A financings, licensed core technology, hired 15 employees, started partnership discussions and begun the process of translating its platform into a product fit for clinical trials.
Yet founder and CEO Alan Crane said the name Tempo refers not to the company's frenetic pace, but to the "temporal release" of multiple drugs from its Nanocell platform technology.
|Related News Press|
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Yale researchers’ technology turns wasted heat into power June 27th, 2016